Page last updated: 2024-08-21

quinazolines and oxyntomodulin

quinazolines has been researched along with oxyntomodulin in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Deshpande, SS; Ghatak, SB; Panchal, SJ; Patel, DS; Shanker, N; Srivastava, A	1
Bakris, GL; Flynn, C	1
Bellver-Sanchis, A; Griñán-Ferré, C; Kondengaden, SM; Marsal-García, L; Pallàs, M; Turga, RC; Vázquez, S	1

Reviews

2 review(s) available for quinazolines and oxyntomodulin

Article	Year
Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus. Current diabetes reviews, 2011, Volume: 7, Issue:5 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines; Treatment Outcome	2011
Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nature reviews. Nephrology, 2013, Volume: 9, Issue:3 Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin	2013

Article

Year

Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.

Current diabetes reviews, 2011, Volume: 7, Issue:5

Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines; Treatment Outcome

2011

Noninsulin glucose-lowering agents for the treatment of patients on dialysis.

Nature reviews. Nephrology, 2013, Volume: 9, Issue:3

Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin

2013

Other Studies

1 other study(ies) available for quinazolines and oxyntomodulin

Article	Year
Pharmacological inhibition of G9a/GLP restores cognition and reduces oxidative stress, neuroinflammation and β-Amyloid plaques in an early-onset Alzheimer's disease mouse model. Aging, 2019, 12-04, Volume: 11, Issue:23 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition; Cognitive Dysfunction; Gene Expression Regulation; Glucagon-Like Peptides; Hippocampus; Histone-Lysine N-Methyltransferase; Histones; Inflammation; Male; Mice; NF-E2-Related Factor 2; Oxidative Stress; Quinazolines	2019

Article

Year

Pharmacological inhibition of G9a/GLP restores cognition and reduces oxidative stress, neuroinflammation and β-Amyloid plaques in an early-onset Alzheimer's disease mouse model.

Aging, 2019, 12-04, Volume: 11, Issue:23

Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition; Cognitive Dysfunction; Gene Expression Regulation; Glucagon-Like Peptides; Hippocampus; Histone-Lysine N-Methyltransferase; Histones; Inflammation; Male; Mice; NF-E2-Related Factor 2; Oxidative Stress; Quinazolines

2019